Abstract: Disclosed are isolated mutant erythropoietin (EPO) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant EPO peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substitution at position 76. This substitution inhibits erythropoietic activity while retaining their neuroprotection. Also disclosed are methods of treating or inhibiting neuronal degeneration, reducing or inhibiting one or more symptoms associated with neuronal degeneration and/or glaucoma in a subject. The methods include administering a therapeutically effective amount of a isolated mutant erythropoietin EPO polypeptide, an expression vector encoding such a mutant erythropoietin EPO polypeptide, a viral particle including an expression vector, or a composition, thereby treating or inhibiting neuronal degeneration in the subject.
Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
August 15, 2017
Assignee:
Sanofi
Inventors:
Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
Abstract: It is disclosed herein that osteoprotegerin increases human beta cell proliferation and survival. Methods are provided for increasing beta cell proliferation, but contacting a beta cell with an effective amount of osteoprotegerin, a functional fragment, variant or fusion protein thereof. Methods are also provided for treating a human subject with diabetes, comprising administering to the subject a therapeutically effective amount of osteoprotegerin, functional variant or fusion protein thereof.
Type:
Grant
Filed:
February 26, 2016
Date of Patent:
August 8, 2017
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
Abstract: The present invention relates to compositions, methods and kits for delivery of an IGF-1 protein or a functional fragment or variant, derivative thereof to cells or tissues that express proteoglycans. More specifically, the present invention relates to fusion proteins comprising a heparin binding protein (HB) comprising SEQ ID NO: 1 or SEQ ID NO: 2. Other aspects relate to use of a HB-IGF-1 fusion proteins in methods to deliver IGF-1 to the cartilage for the treatment of a cartilage related disease and disorder in a subject.
Type:
Grant
Filed:
June 25, 2013
Date of Patent:
May 2, 2017
Assignee:
The Brigham and Women's Hospital, Inc
Inventors:
Richard T. Lee, Parth Patwari, Francesco Loffredo, James Pancoast, Zheng Xin Dong, Todd Vannelli
Abstract: Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.
Type:
Grant
Filed:
December 13, 2012
Date of Patent:
May 2, 2017
Assignees:
ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
Inventors:
Gangamani S. Beligere, Shamila Manoj, Elaine M. Brate, Frank C. Grenier, David J. Hawksworth, Robert N. Ziemann, Larry G. Birkenmeyer, Bernhard Mueller, Andreas Popp, Susan Brophy
Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
Type:
Grant
Filed:
January 29, 2010
Date of Patent:
March 28, 2017
Assignees:
UNIVERSITE D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Abstract: The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.
Type:
Grant
Filed:
July 18, 2013
Date of Patent:
January 10, 2017
Assignee:
Apogenix AG
Inventors:
Harald Fricke, Michaela Fontenay, Claudia Kunz
Abstract: Screening assays and methods of using same for screening to identify modulator agents or compounds that affect matrix metalloproteinase-2 (MMP-2) mediated activation of toll-like receptor-2 (TLR-2) are described herein. Pharmaceutical and immunogenic compositions comprising agents or compounds that modulate MMP-2 mediated activation of TLR-2 are also encompassed. Methods for modulating MMP-2 mediated activation of TLR-2 using MMP-2 peptides in pharmaceutical and immunogenic compositions, as well as vaccines, are also envisioned. Melanoma is an exemplary tumor type that expresses MMP-2 and for which such pharmaceutical and immunogenic compositions, as well as vaccines, would confer benefit to patients. Also encompassed are methods for reducing MMP-2 mediated activation of TLR-2 and downstream signaling therefrom so as to achieve more effective T cell responses to MMP-2 expressing tumors.
Abstract: Provided is a composition for preventing or treating erectile dysfunction including angiopoietin-4 protein as an active ingredient. Angiopoietin-4 protein increases an endothelial cell-specific protein level to induce regeneration of penile vascular endothelial cells, thereby increasing intracavernous pressure. Thus, angiopoietin-4 protein may be efficiently applied to prevention or treatment of erectile dysfunction.
Type:
Grant
Filed:
November 13, 2013
Date of Patent:
November 22, 2016
Assignee:
INHA INDUSTRY PARTNERSHIP INSTITUTE
Inventors:
Jun Kyu Suh, Ji Kan Ryu, Mi Hye Kwon, Gou Young Koh
Abstract: The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.
Type:
Grant
Filed:
September 5, 2012
Date of Patent:
October 4, 2016
Assignee:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
Abstract: The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies.
Type:
Grant
Filed:
May 7, 2013
Date of Patent:
September 13, 2016
Assignee:
Amgen Inc.
Inventors:
Daniel T. Mytych, Narendra Chirmule, Dohan K. Weeraratne
Abstract: The present invention relates to compositions, methods and kits for delivery of active agents (X) to cells or tissues that express proteoglycans. More specifically, the present invention relates to conjugates comprising (HB-linker)n-Xm-(linker-HB)o, where HB is a heparin binding protein, X is an active agents such as a therapeutic protein (including a functional fragment or variant thereof), or a therapeutic small molecule, linker is a linker entity and m is an integer of at least 1, and n+o is an integer of at least 1. Other aspects relate to use of a HB-X conjugate in methods to deliver active agents to cartilage for the treatment of cartilage related disease and disorders, the use of the HB-X conjugate in methods to deliver active agents to neuronal tissues (e.g., brain and spinal cord) for the treatment of neurological disorders, and the use of the HB-X conjugates in methods for the treatment of eye conditions and disorders and inflammatory conditions and disorders.
Type:
Grant
Filed:
June 25, 2013
Date of Patent:
August 23, 2016
Assignee:
The Brigham and Women's Hospital, Inc.
Inventors:
Richard T. Lee, Parth Patwari, Francesco Loffredo, James Pancoast
Abstract: The present invention provides binding polypeptides (e.g., antibodies or fragments thereof) that specifically bind to a target antigen (e.g., a human antigen, e.g., human PDGFR?) with high affinity. The invention also provides, libraries of binding polypeptides, pharmaceutical compositions, as well as nucleic acids encoding binding polypeptides, recombinant expression vectors and host cells for making such binding polypeptides. Methods of using binding polypeptide of the invention to diagnose and treat disease are also encompassed by the invention.
Type:
Grant
Filed:
December 5, 2012
Date of Patent:
August 16, 2016
Assignee:
X-Body, Inc.
Inventors:
Yan Chen, Richard W. Wagner, Csaba Pazmany
Abstract: The present invention provides a composition for stimulating hair growth in a mammal comprising a modified osteopontin polypeptide in which an RGD domain is inactivated; and a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent. The invention further provides methods of stimulating hair growth in a mammal.
Type:
Grant
Filed:
August 10, 2012
Date of Patent:
July 5, 2016
Assignee:
FOLICUM, AB
Inventors:
Jan Alenfall, Pontus Duner, Anna Hultgardh Nilsson
Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. According to certain embodiments, the antibodies of the invention are selective for ASIC1 and do not bind other acid-sensing ion channels in the absence of ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.
Type:
Grant
Filed:
October 31, 2013
Date of Patent:
June 21, 2016
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
Type:
Grant
Filed:
December 3, 2013
Date of Patent:
June 14, 2016
Assignee:
NOVARTIS AG
Inventors:
Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
Abstract: The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides.
Type:
Grant
Filed:
March 28, 2011
Date of Patent:
May 24, 2016
Inventors:
Bo Wang, Rui Rong Yuan, Wei Lu, Peter C. Dowling